Laruparetigene zovaparvovec

Beacon Therapeutics' gene therapy laru-zova showed improvements in visual function measures, including low luminance visual acuity, in patients with X-linked retinitis pigmentosa at 6-month interim analysis.

Durham-based Atsena Therapeutics has raised $150 million in an oversubscribed Series C financing led by Bain Capital to advance gene therapies for inherited blindness conditions.

Nanoscope Therapeutics' MCO-010 gene therapy demonstrated clinically meaningful vision improvements in 16 out of 18 patients with severe retinitis pigmentosa in a Phase 2 trial, compared to only four of nine in the placebo group.

Bionic Sight's BS01 gene therapy received RMAT designation from the FDA based on Phase 1/2 trial data showing improved light sensitivity and visual acuity in RP patients.

Ocugen's OCU400 gene therapy demonstrated a statistically significant improvement in low-luminance visual acuity in patients with retinitis pigmentosa (RP).